aTYR PHARMA (ATYR) Non-Current Assets (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Non-Current Assets came in at $12.1 million in Q1 2026, down 13.57% YoY from $14.0 million in Q1 2025, and down 5.39% on a QoQ basis from $12.8 million in Q4 2025.
aTYR PHARMA (ATYR) Non-Current Assets (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has 13 years of Non-Current Assets data on file, last reported at $12.1 million in Q1 2026.
- Quarterly Non-Current Assets fell 13.57% year-over-year to $12.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.5 million (down 12.15% YoY) and the FY2025 annual result came in at $12.8 million, down 14.18% from the prior year.
- Non-Current Assets slipped to $12.1 million in Q1 2026, from $12.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $18.3 million in Q2 2023 to a low of $1.7 million in Q1 2022.
- A 5-year average of $13.6 million and a median of $14.9 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets sank 44.59% — and 2023, when it soared 948.28%.
- Tracing ATYR's Non-Current Assets over 5 years: stood at $14.9 million in 2022, then grew by 18.41% to $17.7 million in 2023, then slipped by 15.77% to $14.9 million in 2024, then dropped by 14.18% to $12.8 million in 2025, then retreated by 5.39% to $12.1 million in 2026.
- The last three Non-Current Assets figures came in at $12.1 million (Q1 2026), $12.8 million (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | aTYR PHARMA | 50.00 Mn | -7.42 Mn | - | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.46 Mn |
| Mar 31, 2026 | 12.08 Mn |
| Dec 31, 2025 | 12.77 Mn |
| Sep 30, 2025 | 13.64 Mn |
| Jun 30, 2025 | 14.04 Mn |
| Mar 31, 2025 | 13.97 Mn |
| Dec 31, 2024 | 14.88 Mn |
| Sep 30, 2024 | 15.30 Mn |
| Jun 30, 2024 | 15.64 Mn |
| Mar 31, 2024 | 16.34 Mn |
| Dec 31, 2023 | 17.66 Mn |
| Sep 30, 2023 | 17.77 Mn |
| Jun 30, 2023 | 18.32 Mn |
| Mar 31, 2023 | 17.39 Mn |
| Dec 31, 2022 | 14.92 Mn |
| Sep 30, 2022 | 11.42 Mn |
| Jun 30, 2022 | 2.66 Mn |
| Mar 31, 2022 | 1.66 Mn |
| Dec 31, 2021 | 1.97 Mn |
| Sep 30, 2021 | 2.34 Mn |